Abstract: 5?-monophosphate nucleotide and a mixture thereof are used in preparation of a drug or food for improving a mitochondrial function. 5?-Monophosphate nucleotide is a mixture of a 5?-adenosine monophosphate and 5?-disodium uridine which are produced by means of enzymatic degradation of a ribonucleic acid as a raw material and has a purity of 99% or more. The 5? nucleotide mixture contains: 23-78% of CMP, 6-44% of AMP, 7-40% of UMP, 7-51% of GMP, and IMP being 0, or greater than 0 and not higher than 2.5%. It has been found 5?-monophosphate nucleotide and the mixture thereof can improve the mitochondrial function of H2O2-induced senescence fibroblasts.

Abstract: A nucleotide probiotic capsule for delaying aging has a capsule shell and contents. The contents include four exogenous nucleotides and five probiotics. The exogenous nucleotides include 5?-cytidine monophosphate (5?-CMP), 5?-adenosine monophosphate (5?-AMP), 5?-disodium uridylate (5?-UMPNa2) and 5?-disodium guanylate (5?-GMPNa2), and the probiotics include Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, etc. Each of the probiotics has a content greater than 1×107 CFU/g. The nucleotide probiotic capsule capable of scavenging free radicals in the body, inhibiting oxidative damage of the free radicals to the body, and prolonging the cell life.

Abstract: A nucleotide is useful in preparation of drugs for preventing and treating allergic rhinitis and other diseases or in functional foods for relieving allergic rhinitis symptoms. The nucleotide is a mixture of five nucleotides, i.e., CMP, AMP, UMP, GMP and IMP, with a small molecular weight, rapid absorption into the human body and high bioavailability. The intake of nucleotide can play a role of treating allergic diseases by alleviating allergic rhinitis symptoms, relieving allergy-induced splenomegaly, significantly reducing histamine levels in serum and nasal lavage fluid, and effectively regulating inflammatory factors.

Abstract: Disclosed are two myocardial peptides, whose amino acid sequences are Trp-Ser-Asn-Val-Leu-Arg-Gly-Met-Gly-Gly-Ala-Phe and Lys-Gly-Ala-Trp-Ser-Asn-Val-Leu-Arg-Gly-Met-Gly-Gly-Ala-Phe respectively, wherein the latter can be obtained by extracting from myocardial peptides solution. The myocardial peptides can be used in the produce of a medicament for preventing and/or treating myocardial ischemia.

Abstract: Disclosed are two myocardial peptides, whose amino acid sequences are Trp-Ser-Asn-Val-Leu-Arg-Gly-Met-Gly-Gly-Ala-Phe and Lys-Gly-Ala-Trp-Ser-Asn-Val-Leu-Arg-Gly-Met-Gly-Gly-Ala-Phe respectively, wherein the latter can be obtained by extracting from myocardial peptides solution. The myocardial peptides can be used in the produce of a medicament for preventing and/or treating myocardial ischemia.

Abstract: The present invention relates to a cardio myopeptidin which is isolated from the hearts of non-human healthy mammals. The molecular weight of the cardio myopeptidin is less than 10000 Dalton, the peptide content thereof being 75%˜90%, the free amino acid content 6%˜15%, the ribonucleic acid content less than 2%, and the deoxyribonucleic acid content less than 7.5%. The present invention further provides a method of producing the cardio myopeptidin and the use thereof in producing pharmaceuticals for treating cardiac disorders, specifically the use in producing pharmaceuticals for treating myocardial ischemic and reperfusion injury. The cardio myopeptidin of the present invention can work directly on myocytes, promoting the repair of injuries caused by various reasons, and providing a new way to relieve ischemic and reperfusion injury, and to promote the repair of injured myocardium.

Abstract: The present invention relates to a cardio myopeptidin which is isolated from the hearts of non-human healthy mammals. The molecular weight of the cardio myopeptidin is less than 10000 Dalton, the peptide content thereof being 75%˜90%, the free amino acid content 6%˜15%, the ribonucleic acid content less than 2%, and the deoxyribonucleic acid content less than 7.5%. The present invention further provides a method of producing the cardio myopeptidin and the use thereof in producing pharmaceuticals for treating cardiac disorders, specifically the use in producing pharmaceuticals for treating myocardial ischemic and reperfusion injury. The cardio myopeptidin of the present invention can work directly on myocytes, promoting the repair of injuries caused by various reasons, and providing a new way to relieve ischemic and reperfusion injury, and to promote the repair of injured myocardium.